CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
000963 Huadong Medicine
- 38.85
- +1.44+3.85%
Market Closed Apr 30 15:00 CST
68.15BMarket Cap19.12P/E (TTM)
39.19High37.30Low159.00KlotVolume37.42Open37.41Pre Close610.61MTurnover0.91%Turnover Ratio19.41P/E (Static)1.75BShares40.8052wk High2.83P/B68.06BFloat Cap25.6152wk Low41.15Limit Up1.75BShs Float52.20Historical High33.67Limit Down5.05%Amplitude-3.38Historical Low0.93Dividend TTM38.40Avg Price64.71KlotAsk2.39%Div YieldTTM100Lot Size83.90KlotBid
Huadong Medicine Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 3.12%10.74B | 3.16%41.91B | 3.56%31.48B | 2.84%20.97B | 2.93%10.41B | 7.71%40.62B | 9.10%30.39B | 12.02%20.39B | 13.23%10.11B | 9.12%37.71B |
| Operating revenue | 3.12%10.74B | 3.16%41.91B | 3.56%31.48B | 2.84%20.97B | 2.93%10.41B | 7.71%40.62B | 9.10%30.39B | 12.02%20.39B | 13.23%10.11B | 9.12%37.71B |
| Other operating revenue | ---- | 9.62%397.3M | ---- | 4.01%142.98M | ---- | 60.37%362.43M | ---- | 50.97%137.47M | ---- | 55.26%226M |
| Total operating cost | 3.09%9.62B | 1.11%37.49B | 2.72%28.29B | 2.35%18.88B | 2.42%9.33B | 7.27%37.08B | 8.33%27.54B | 11.67%18.44B | 13.49%9.11B | 8.96%34.57B |
| Operating cost | 1.84%7.21B | 1.92%27.99B | 2.51%21.23B | 1.38%14.11B | 4.21%7.08B | 6.93%27.46B | 8.97%20.71B | 13.67%13.92B | 14.81%6.79B | 7.20%25.68B |
| Operating tax surcharges | 1.65%57.27M | 7.76%250.64M | 5.63%163.79M | 4.05%111.01M | 5.99%56.33M | 11.65%232.59M | 6.38%155.06M | 11.03%106.69M | 6.58%53.15M | 17.53%208.32M |
| Operating expense | -6.58%1.47B | -3.56%6.41B | 1.40%4.73B | 6.19%3.27B | -4.16%1.57B | 4.90%6.65B | 3.53%4.66B | 1.68%3.08B | 14.59%1.64B | 16.79%6.33B |
| Administration expense | 6.03%355.4M | -1.61%1.4B | 6.62%1.18B | -0.95%714.63M | 1.54%335.17M | 13.73%1.42B | 15.33%1.11B | 26.12%721.48M | 9.08%330.09M | 7.01%1.25B |
| Financial expense | 93.49%14.62M | -56.51%22.26M | -40.63%38.02M | -58.06%23.42M | -74.08%7.56M | -34.59%51.19M | 230.55%64.03M | 925.12%55.85M | 261.66%29.15M | 254.50%78.26M |
| -Interest expense (Financial expense) | 12.47%25.92M | -15.32%101.2M | 2.69%86.59M | 0.27%55.55M | -33.12%23.05M | -6.38%119.51M | 51.30%84.32M | 32.55%55.4M | 64.47%34.47M | 44.10%127.65M |
| -Interest Income (Financial expense) | -13.94%-27.81M | -10.58%-104M | -29.72%-80.01M | -60.93%-53.14M | -95.41%-24.41M | 9.00%-94.05M | 18.60%-61.68M | 33.90%-33.02M | 48.30%-12.49M | -28.54%-103.35M |
| Research and development | 82.99%515.38M | 12.19%1.43B | 12.83%948.66M | 15.17%643.11M | 6.08%281.64M | 25.08%1.27B | 6.68%840.79M | -1.45%558.41M | -16.83%265.49M | 3.71%1.02B |
| Credit Impairment Loss | ---- | -335.42%-112.18M | -37.88%-57.94M | -59.03%-57.94M | ---- | 62.49%-25.76M | 41.61%-42.02M | 49.38%-36.43M | ---- | -64.76%-68.69M |
| Asset Impairment Loss | ---- | -528.94%-41.01M | ---- | ---- | ---- | -70.60%-6.52M | ---3.18M | ---3.18M | ---- | 77.40%-3.82M |
| Other net revenue | 323.99%16.48M | 1.11%-87.95M | 118.10%26.51M | 95.01%-7.15M | 85.10%-7.36M | -5.18%-88.94M | -196.03%-146.45M | -306.01%-143.26M | -195.02%-49.37M | -528.20%-84.56M |
| Fair value change income | ---- | ---- | ---- | ---- | ---25.36K | -148.32%-13.76M | ---6.62M | ---5.1M | ---- | --28.47M |
| Invest income | 9.62%-42.62M | 41.20%-129.19M | 48.64%-86.71M | 65.05%-47.85M | 23.63%-47.16M | -55.21%-219.71M | -70.25%-168.84M | -155.96%-136.89M | -120.85%-61.75M | -46.98%-141.56M |
| -Including: Investment income associates | 24.68%-28.25M | 63.66%-68.45M | 62.45%-54.56M | 79.03%-25.26M | 28.99%-37.5M | -62.94%-188.39M | -79.47%-145.31M | -179.12%-120.43M | -154.37%-52.82M | -116.38%-115.62M |
| Asset deal income | -1,055.84%-14.54M | -226.47%-5.46M | -39.32%2.18M | 39.99%4.93M | 169.15%1.52M | -47.69%4.32M | -35.68%3.59M | -58.62%3.52M | -494.37%-2.2M | 26,209.73%8.26M |
| Other revenue | 92.22%73.64M | 15.88%199.89M | 139.29%168.98M | 169.17%93.71M | 162.72%38.31M | 85.91%172.49M | -39.17%70.62M | -57.36%34.81M | 36.68%14.58M | -46.89%92.78M |
| Operating profit | 5.61%1.13B | 25.25%4.32B | 18.71%3.22B | 15.72%2.08B | 12.39%1.07B | 12.79%3.45B | 13.49%2.71B | 9.25%1.8B | 7.46%953.94M | 7.20%3.06B |
| Add:Non operating Income | -40.64%769.1K | 74.11%88.01M | 110.42%7.44M | 75.66%5.22M | -6.74%1.3M | 564.38%50.55M | -29.74%3.54M | -31.53%2.97M | 67.05%1.39M | 183.66%7.61M |
| Less:Non operating expense | 439.64%28.08M | 196.70%111.23M | 270.46%88.91M | 131.83%37.78M | -13.99%5.2M | -1.18%37.49M | -11.34%24M | 88.17%16.3M | 12.94%6.05M | 22.93%37.94M |
| Total profit | 3.44%1.1B | 24.11%4.3B | 16.58%3.13B | 14.76%2.05B | 12.53%1.07B | 14.35%3.47B | 13.68%2.69B | 8.73%1.79B | 7.48%949.28M | 7.20%3.03B |
| Less:Income tax cost | -8.16%190.97M | 30.30%807.33M | 15.51%571.28M | 4.36%360.34M | 9.82%207.94M | 24.29%619.59M | 38.06%494.56M | 19.91%345.28M | 11.94%189.35M | 1.96%498.5M |
| Net profit | 6.25%913.98M | 22.76%3.49B | 16.82%2.56B | 17.25%1.69B | 13.20%860.25M | 12.39%2.85B | 9.33%2.19B | 6.35%1.44B | 6.43%759.93M | 8.30%2.53B |
| Net profit from continuing operation | 6.25%913.98M | 22.76%3.49B | 16.82%2.56B | 17.25%1.69B | 13.20%860.25M | 12.39%2.85B | 9.33%2.19B | 6.35%1.44B | 6.43%759.93M | 8.30%2.53B |
| Less:Minority Profit | 66.56%-724.3K | -337.77%-17.92M | -93.83%277.57K | -229.42%-7.81M | -146.68%-2.17M | -77.44%7.54M | -81.89%4.5M | -54.77%6.03M | -52.00%4.64M | -9.69%33.41M |
| Net profit of parent company owners | 6.06%914.71M | 23.72%3.51B | 17.05%2.56B | 18.29%1.7B | 14.18%862.41M | 13.59%2.84B | 10.48%2.19B | 6.96%1.43B | 7.23%755.28M | 8.58%2.5B |
| Earning per share | ||||||||||
| Basic earning per share | 5.98%0.5224 | 23.60%2.0046 | 17.06%1.4644 | 18.07%0.9675 | 14.20%0.4929 | 13.55%1.6219 | 10.47%1.251 | 6.96%0.8194 | 7.23%0.4316 | 8.58%1.4283 |
| Diluted earning per share | 5.78%0.5213 | 23.61%2.0034 | 17.08%1.4639 | 18.27%0.9686 | 14.21%0.4928 | 13.47%1.6207 | 10.41%1.2503 | 6.91%0.819 | 7.20%0.4315 | 8.58%1.4283 |
| Other composite income | 102.13%82.04M | -120.31%-10.26M | 554.51%17.68M | 29.29%-6.29M | 229.47%40.59M | 223.84%50.51M | 79.56%-3.89M | 90.95%-8.89M | -108.80%-31.35M | -69.40%-40.78M |
| Other composite income of parent company owners | 102.13%82.04M | -120.31%-10.26M | 554.51%17.68M | 29.29%-6.29M | 229.47%40.59M | 223.84%50.51M | 79.56%-3.89M | 90.95%-8.89M | -108.80%-31.35M | -69.40%-40.78M |
| Total composite income | 10.57%996.03M | 20.26%3.48B | 17.84%2.58B | 17.54%1.68B | 23.64%900.84M | 16.26%2.9B | 10.18%2.19B | 13.96%1.43B | 4.23%728.57M | 7.66%2.49B |
| Total composite income of parent company owners | 10.38%996.75M | 21.20%3.5B | 18.07%2.58B | 18.58%1.69B | 24.74%903M | 17.53%2.89B | 11.35%2.19B | 14.70%1.42B | 5.02%723.93M | 7.94%2.46B |
| Total composite income of minority owners | 66.56%-724.3K | -337.77%-17.92M | -93.83%277.57K | -229.42%-7.81M | -146.68%-2.17M | -77.44%7.54M | -81.89%4.5M | -54.77%6.03M | -52.00%4.64M | -9.69%33.41M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.